Intervet sees 6% global growth

Outpacing market growth, EBIT before incidentals increased 2% to EUR 213 million, resulting in an EBIT margin of 18.9%. Divestments and acquisitions had a negative impact on revenues of 3%.

In Europe, autonomous growth was 5%, while in North America, revenues from ongoing operations grew 12%. At the end of the year, Intervet received important product approvals for Zilmax®, a feed additive for cattle and PreveNile®, a West Nile Virus vaccine for horses.

Sign up for our
regular news updates

Latest Pig Industry News

•   Ontario Pork Responds to OFPMC's Decision
•   APL Responds to Piggery Health Concerns
•   Decision on Future of Ontario Pork Made
•   ALMA Launches New Web Site
•   Weekly Roberts Report
•   Pork Commentary: Road Trip to Ukraine and Russia
•   EU Pig Prices: Trend Points to Stability
•   CME: Livestock and Grain Markets Rattled
•   Classical Swine Fever: Planning for the Worst
•   Weekly Outlook: Lack of Confidence in Demand